CA2467893A1 - Cellules presentatrices d'antigene modifiees - Google Patents

Cellules presentatrices d'antigene modifiees Download PDF

Info

Publication number
CA2467893A1
CA2467893A1 CA002467893A CA2467893A CA2467893A1 CA 2467893 A1 CA2467893 A1 CA 2467893A1 CA 002467893 A CA002467893 A CA 002467893A CA 2467893 A CA2467893 A CA 2467893A CA 2467893 A1 CA2467893 A1 CA 2467893A1
Authority
CA
Canada
Prior art keywords
cell
antigen
molecule
cells
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002467893A
Other languages
English (en)
Inventor
Naoto Hirano
Marcus Butler
Lee M. Nadler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2467893A1 publication Critical patent/CA2467893A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention a trait à des cellules présentatrices d'antigène présentant une spécificité contre un antigène sélectionné et des procédés permettant la fabrication de telles cellules. L'invention a trait également à un procédé de sélection de cellules présentatrices d'antigène efficaces utilisant des constructions de fusion de gènes rapporteurs. Les cellules présentatrices d'antigène à efficacité élevée de l'invention fournissent un stratégie thérapeutique de modulation de réponses immunitaires pour une variété de maladies.
CA002467893A 2001-11-20 2002-11-20 Cellules presentatrices d'antigene modifiees Abandoned CA2467893A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33192801P 2001-11-20 2001-11-20
US60/331,928 2001-11-20
PCT/US2002/037123 WO2003065977A2 (fr) 2001-11-20 2002-11-20 Cellules presentatrices d'antigene modifiees

Publications (1)

Publication Number Publication Date
CA2467893A1 true CA2467893A1 (fr) 2003-08-14

Family

ID=27734220

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002467893A Abandoned CA2467893A1 (fr) 2001-11-20 2002-11-20 Cellules presentatrices d'antigene modifiees

Country Status (4)

Country Link
EP (1) EP1458241A4 (fr)
AU (1) AU2002365938A1 (fr)
CA (1) CA2467893A1 (fr)
WO (1) WO2003065977A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7955845B2 (en) * 2001-11-20 2011-06-07 Dana Farber Cancer Institute, Inc. Modified antigen-presenting cells
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
WO2003057171A2 (fr) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation et developpement de lymphocytes t par mise en oeuvre d'une plate-forme de signalisation multivalente etablie
US7638326B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
EP2591786B1 (fr) 2003-10-16 2017-04-12 Cancure Limited Compositions immunomodulatrices et leurs utilisations
WO2005118788A2 (fr) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Cellules de presentation de nouveaux antigenes artificiels, et utilisations correspondantes
KR102606929B1 (ko) * 2016-11-07 2023-11-27 제노비에 에이비 동족 항원과 t-세포 수용체 상호작용의 발견 및 특징규명을 위한 조작된 2-부분 세포 디바이스
EP4019625A1 (fr) * 2016-11-07 2022-06-29 Genovie AB Système à composants multiples génétiquement modifiés utilisé pour la sélections de récepteurs de lymphocytes t, lymphocytes t et celules cellules présentatrices d'antigènes modifiées.
ES2900151T3 (es) 2016-11-07 2022-03-16 Genovie Ab Un dispositivo de dos partes para la síntesis del receptor de linfocitos T0 e integración genómica estable en células presentadoras del TCR

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5738852A (en) * 1993-04-20 1998-04-14 Solis Therapeutics, Inc. Methods of enhancing antigen-specific T cell responses
WO2001080833A1 (fr) * 2000-04-20 2001-11-01 Salvatore Albani Procedes d'isolation, de quantification, de caracterisation et de modulation de cellules t specifiques des antigenes

Also Published As

Publication number Publication date
WO2003065977A9 (fr) 2003-10-16
WO2003065977A2 (fr) 2003-08-14
EP1458241A4 (fr) 2005-11-09
AU2002365938A1 (en) 2003-09-02
EP1458241A2 (fr) 2004-09-22
WO2003065977A3 (fr) 2003-12-11
AU2002365938A8 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
CA2566903A1 (fr) Cellules de presentation de l'antigene modifiees
JP7260182B2 (ja) β２ミクログロブリン欠損細胞
JP7130571B2 (ja) Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用
CA2154445C (fr) Ciblage lysosomal d'immunogenes
US5962320A (en) Engineered antigen presenting cells and methods for their use
JP4588296B2 (ja) キメラワクチン
KR20170126500A (ko) Mhc 세포 라이브러리를 이용하여 신규한 면역원성 t 세포 에피토프를 검출하고 신규한 항원-특이적 t 세포 수용체를 단리하는 방법
EP1086224B1 (fr) Proteines de fusion de microglobuline b2 et variantes de haute affinite
JP2000506125A (ja) 免疫調節のための医薬組成物
CA2467893A1 (fr) Cellules presentatrices d'antigene modifiees
WO2020145222A1 (fr) Nouveaux néoantigènes et immunothérapie anticancéreuse l'utilisant
US9475841B2 (en) Melanoma antigen peptide and uses thereof
AU2018316253A1 (en) LMP1-expressing cells and methods of use thereof
CA2322659A1 (fr) Compositions et methodes pour provoquer une reponse des cellules t par des vaccins a base de genes
JP6363996B2 (ja) 免疫原性が低下した凝固因子ｖｉｉｉ
AU755156B2 (en) Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby
US9573975B2 (en) Melanoma antigen peptide and uses thereof
Westerman Tumor membrane liposomes with the addition of purified costimulatory molecules as a novel cell-free tumor vaccine
Poloso Protein transfer of immunostimulatory molecules for use in therapeutic cancer vaccines
Hofstetter Investigating the Requirements for Expansion and Maintenance of a Mouse Polyomavirus-specific MHC Class Ib-Restricted CD8 T Cell Response
Halstead Modulating CD8+ T cell responses in vivo
Jordan The T cell response to optimal tumor peptide vaccines
Dyall The use of optimal MHC class I-binding peptides to study T cell selection, recognition and activation
AU2480001A (en) Immunotherapy using cytotoxic T lymphocytes (CTL)

Legal Events

Date Code Title Description
FZDE Discontinued